| 1 | ONCSSF3 ;Hines OIFO/GWB - SITE-SPECIFIC FACTOR 3 (165.5,44.3) ;11/20/03
|
---|
| 2 | ;;2.11;ONCOLOGY;**40**;Mar 07, 1995
|
---|
| 3 | ;
|
---|
| 4 | ;SITE-SPECIFIC FACTOR 3 (165.5,44.3)
|
---|
| 5 | SSF3IT ;INPUT TRANSFORM
|
---|
| 6 | ;
|
---|
| 7 | S PS=$P($G(^ONCO(165.5,D0,2)),U,1)
|
---|
| 8 | I PS="" K X W " No PRIMARY SITE defined for this primary" Q
|
---|
| 9 | S MO=$$HIST^ONCFUNC(D0)
|
---|
| 10 | ;
|
---|
| 11 | S SSFIEN=$S($D(^ONCO(164.52,"C",PS_"-3")):$O(^ONCO(164.52,"C",PS_"-3",0)),1:1)
|
---|
| 12 | ;
|
---|
| 13 | ;Malignant Melanoma of Skin, Vulva, Penis, Scrotum
|
---|
| 14 | I $$MELANOMA^ONCOU55(D0) D
|
---|
| 15 | .S MELIEN=$O(^ONCO(164.52,"B","CLINICAL STATUS OF LYMPH NODE ",0))
|
---|
| 16 | .I $E(PS,3,4)=44 S SSFIEN=MELIEN Q
|
---|
| 17 | .I $E(PS,3,4)=51 S SSFIEN=MELIEN Q
|
---|
| 18 | .I $E(PS,3,4)=60 S SSFIEN=MELIEN Q
|
---|
| 19 | .I PS=67632 S SSFIEN=MELIEN Q
|
---|
| 20 | ;
|
---|
| 21 | ;Hodgkin and Non-Hodgkin Lymphomas of All Sites
|
---|
| 22 | I $$LYMPHOMA^ONCFUNC(D0) S SSFIEN=$O(^ONCO(164.52,"B","IPI SCORE",0))
|
---|
| 23 | ;
|
---|
| 24 | ;Mycosis Fungoides and Sezary Disease of Skin, Vulva, Penis, Scrotum
|
---|
| 25 | ;Kaposi Sarcoma of All Sites
|
---|
| 26 | I (MO=97003)!(MO=97013)!($E(MO,1,4)=9140) S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0))
|
---|
| 27 | ;
|
---|
| 28 | ;Hematopoietic, Reticuloendothelial, Immunoproliferative, and
|
---|
| 29 | ;Myeloproliferative Neoplasms
|
---|
| 30 | I (MO'<97310)&(MO'>99899) S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0))
|
---|
| 31 | ;
|
---|
| 32 | ;Retinoblastoma
|
---|
| 33 | I $E(MO,1,3)=951 S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0)) G SSF3I
|
---|
| 34 | ;
|
---|
| 35 | ;Breast
|
---|
| 36 | I $E(PS,3,4)=50,+X>0,+X<90 D G ITEX
|
---|
| 37 | .I X'?3N D K X Q
|
---|
| 38 | ..I X?1N W !!," For ",X," enter 00",X," "
|
---|
| 39 | ..I X?2N W !!," For ",X," enter 0",X," "
|
---|
| 40 | .W " ",X," nodes positive"
|
---|
| 41 | ;
|
---|
| 42 | SSF3I I '$D(^ONCO(164.52,SSFIEN,1,"B",X)) K X Q
|
---|
| 43 | S SSF=$O(^ONCO(164.52,SSFIEN,1,"B",X,0))
|
---|
| 44 | W " ",$P(^ONCO(164.52,SSFIEN,1,SSF,0),U,2)
|
---|
| 45 | ITEX K PS,SSFIEN,SSF,MO,MELING Q
|
---|
| 46 | ;
|
---|
| 47 | SSF3OT ;OUTPUT TRANSFORM
|
---|
| 48 | ;
|
---|
| 49 | S PS=$P($G(^ONCO(165.5,D0,2)),U,1)
|
---|
| 50 | Q:PS=""
|
---|
| 51 | S MO=$$HIST^ONCFUNC(D0)
|
---|
| 52 | ;
|
---|
| 53 | S SSFIEN=$S($D(^ONCO(164.52,"C",PS_"-3")):$O(^ONCO(164.52,"C",PS_"-3",0)),1:1)
|
---|
| 54 | ;
|
---|
| 55 | ;Malignant Melanoma of Skin, Vulva, Penis, Scrotum
|
---|
| 56 | I $$MELANOMA^ONCOU55(D0) D
|
---|
| 57 | .S MELIEN=$O(^ONCO(164.52,"B","CLINICAL STATUS OF LYMPH NODE ",0))
|
---|
| 58 | .I $E(PS,3,4)=44 S SSFIEN=MELIEN Q
|
---|
| 59 | .I $E(PS,3,4)=51 S SSFIEN=MELIEN Q
|
---|
| 60 | .I $E(PS,3,4)=60 S SSFIEN=MELIEN Q
|
---|
| 61 | .I PS=67632 S SSFIEN=MELIEN Q
|
---|
| 62 | ;
|
---|
| 63 | ;Hodgkin and Non-Hodgkin Lymphomas of All Sites
|
---|
| 64 | I $$LYMPHOMA^ONCFUNC(D0) S SSFIEN=$O(^ONCO(164.52,"B","IPI SCORE",0))
|
---|
| 65 | ;
|
---|
| 66 | ;Mycosis Fungoides and Sezary Disease of Skin, Vulva, Penis, Scrotum
|
---|
| 67 | ;Kaposi Sarcoma of All Sites
|
---|
| 68 | I (MO=97003)!(MO=97013)!($E(MO,1,4)=9140) S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0))
|
---|
| 69 | ;
|
---|
| 70 | ;Hematopoietic, Reticuloendothelial, Immunoproliferative, and
|
---|
| 71 | I (MO'<97310)&(MO'>99899) S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0))
|
---|
| 72 | ;
|
---|
| 73 | ;Retinoblastoma
|
---|
| 74 | I $E(MO,1,3)=951 S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0)) G SSF3O
|
---|
| 75 | ;
|
---|
| 76 | ;Breast
|
---|
| 77 | I $E(PS,3,4)=50,+Y>0,+Y<90 S Y=Y_" nodes positive" G OTEX
|
---|
| 78 | ;
|
---|
| 79 | SSF3O S SSF=$O(^ONCO(164.52,SSFIEN,1,"B",Y,0)) I SSF="" G OTEX
|
---|
| 80 | S Y=$P($G(^ONCO(164.52,SSFIEN,1,SSF,0)),U,2)
|
---|
| 81 | OTEX K PS,SSFIEN,SSF,MO Q
|
---|
| 82 | ;
|
---|
| 83 | SSF3HP ;HELP
|
---|
| 84 | ;
|
---|
| 85 | S PS=$P($G(^ONCO(165.5,D0,2)),U,1)
|
---|
| 86 | Q:PS=""
|
---|
| 87 | S MO=$$HIST^ONCFUNC(D0)
|
---|
| 88 | ;
|
---|
| 89 | S SSFIEN=$S($D(^ONCO(164.52,"C",PS_"-3")):$O(^ONCO(164.52,"C",PS_"-3",0)),1:1)
|
---|
| 90 | ;
|
---|
| 91 | ;Malignant Melanoma of Skin, Vulva, Penis, Scrotum
|
---|
| 92 | I $$MELANOMA^ONCOU55(D0) D
|
---|
| 93 | .S MELIEN=$O(^ONCO(164.52,"B","CLINICAL STATUS OF LYMPH NODE ",0))
|
---|
| 94 | .I $E(PS,3,4)=44 S SSFIEN=MELIEN Q
|
---|
| 95 | .I $E(PS,3,4)=51 S SSFIEN=MELIEN Q
|
---|
| 96 | .I $E(PS,3,4)=60 S SSFIEN=MELIEN Q
|
---|
| 97 | .I PS=67632 S SSFIEN=MELIEN Q
|
---|
| 98 | ;
|
---|
| 99 | ;Hodgkin and Non-Hodgkin Lymphomas of All Sites
|
---|
| 100 | I $$LYMPHOMA^ONCFUNC(D0) S SSFIEN=$O(^ONCO(164.52,"B","IPI SCORE",0))
|
---|
| 101 | ;
|
---|
| 102 | ;Mycosis Fungoides and Sezary Disease of Skin, Vulva, Penis, Scrotum
|
---|
| 103 | ;Kaposi Sarcoma of All Sites
|
---|
| 104 | I (MO=97003)!(MO=97013)!($E(MO,1,4)=9140) S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0))
|
---|
| 105 | ;
|
---|
| 106 | ;Hematopoietic, Reticuloendothelial, Immunoproliferative, and
|
---|
| 107 | I (MO'<97310)&(MO'>99899) S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0))
|
---|
| 108 | ;
|
---|
| 109 | ;Retinoblastoma
|
---|
| 110 | I $E(MO,1,3)=951 S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0))
|
---|
| 111 | ;
|
---|
| 112 | W !," SITE-SPECIFIC FACTOR 3 for " D
|
---|
| 113 | .I MO=97003 W "MYCOSIS FUNGOIDES of ",$P(^ONCO(164,PS,0),U,1)," (",$P(^ONCO(164,PS,0),U,2),")" Q
|
---|
| 114 | .I MO=97013 W "SEZARY SYNDROME of ",$P(^ONCO(164,PS,0),U,1)," (",$P(^ONCO(164,PS,0),U,2),")" Q
|
---|
| 115 | .I $E(MO,1,3)=951 W "RETINOBLASTOMA of ",$P(^ONCO(164,PS,0),U,1)," (",$P(^ONCO(164,PS,0),U,2),")" Q
|
---|
| 116 | .I $$MELANOMA^ONCOU55(D0),($E(PS,3,4)=44)!($E(PS,3,4)=51)!($E(PS,3,4)=60)!(PS=67632)!($E(PS,3,4)=69) W "MALIGNANT MELANOMA of ",$P(^ONCO(164,PS,0),U,1)," (",$P(^ONCO(164,PS,0),U,2),")" Q
|
---|
| 117 | .I $E(MO,1,4)=9140 W "KAPOSI SARCOMA of ALL SITES" Q
|
---|
| 118 | .I $$LYMPHOMA^ONCFUNC(D0) W "HODGKIN AND NON-HODGKIN LYMPHOMAS of ALL SITES" Q
|
---|
| 119 | .I (MO'<97310)&(MO'>99899) W $P(^ONCO(169.3,MO,0),U,1)," (",$P(^ONCO(169.3,MO,0),U,2),")" Q
|
---|
| 120 | .W $P(^ONCO(164,PS,0),U,1)," (",$P(^ONCO(164,PS,0),U,2),")"
|
---|
| 121 | W !," ",$P(^ONCO(164.52,SSFIEN,0),U,1)
|
---|
| 122 | ;S SSF=0 F S SSF=$O(^ONCO(164.52,SSFIEN,1,SSF)) Q:SSF'>0 D
|
---|
| 123 | ;.S TAB=6
|
---|
| 124 | ;.I ($P(^ONCO(164.52,SSFIEN,0),U,1)="NUMBER OF POSITIVE IPSILATERAL AXILLARY LYMPH NODES") S TAB=10
|
---|
| 125 | ;.W " ",$P(^ONCO(164.52,SSFIEN,1,SSF,0),U,1),?TAB,$P(^ONCO(164.52,SSFIEN,1,SSF,0),U,2),!
|
---|
| 126 | K PS,SSFIEN,SSF,MO Q
|
---|